|
Sa is associated with severe rheumatoid arthritis (RA) |
||||||
| Sa+ RA |
Sa- RA |
RF+ RA |
RF- RA |
SE+ RA |
SE- RA |
|
| (n=23) |
(n=83) |
(n=70) |
(n=36) |
(n=62) |
(n=44) |
|
|
|
||||||
| Male (%) |
14 (61)* |
23 (28) |
27 (39) |
10 (28) |
24(39) |
13 (30) |
| Age |
48 ± 15 |
46 ± 13 |
47 ± 12 |
44 ± 15 |
49 ± 13* |
42 ± 13 |
| Duration of symptoms (weeks) |
36 ± 25 |
30 ± 18 |
33 ± 17 |
29 ± 24 |
32 ± 15 |
31 ± 25 |
| Initial visit |
||||||
| Swollen joints |
18 ± 12* |
13 ± 9 |
13 ± 9 |
16 ± 10 |
13 ± 9 |
14 ± 11 |
| Nodules |
1(4) |
5 (6) |
5 (7) |
1 (3) |
5(8) |
1 (2) |
| CRP (mg/dl) |
2.6 ± 3* |
1.6 ± 1.4 |
1.9 ± 1.8 |
1.9 ± 2.1 |
1.7 ± 1.5 |
2.1 ± 2.4 |
| On DMARDs (%) |
11 (48) |
31 (37) |
28 (40) |
14 (39) |
24 (39) |
18 (41) |
| On prednisone (%) |
12 (52) |
29 (35) |
25 (36) |
16 (44) |
26 (42) |
15 (34) |
| Multiple erosions (%)† |
7 (30) |
12 (14) |
12 (17) |
7 (19) |
12 (19) |
7 (16) |
| One year visit |
||||||
| Swollen joints |
8 ± 9 |
8 ± 10 |
9 ± 11 |
7 ± 7 |
10 ± 11* |
5 ± 6 |
| CRP (mg/dl) |
1.1 ± 0.7 |
1.2 ± 1.8 |
1.3 ± 1.9 |
0.9 ± 0.5 |
1.4 ± 2.1 |
0.9 ± 0.3 |
| Number of DMARDs |
1.4 ± 0.8* |
0.9 ± 0.7 |
0.9 ± 0.7 |
1.0 ± 0.8 |
0.9 ± 0.7 |
1.1 ± 0.8 |
| Prednisone (mg/day) |
4.8 ± 6.0* |
1.8 ± 3.3 |
2.7 ± 4.8 |
2.0 ± 2.5 |
2.7 ± 4.0 |
2.1 ± 3.9 |
| Multiple erosions (%)† |
12 (60)* |
27 (33) |
24 (34) |
14 (39) |
25 (42) |
13 (30) |
| Inactive disease (%) |
0 |
9 (12) |
3 (4) |
6 (17) |
4 (7) |
5 (11) |
|
Independent comparisons are made between Sa+ and Sa- RA, RF+ and RF- RA, SE+ and SE- RA. *P<0.05.†One hundred and two out of 106 (96%) of the patients had 1 year radiographs available for analysis. Multiple erosions included all patients with two or more erosions that involved at least two separate joint areas. RF, Rheumatoid factor; SE, shared epitope; CRP, C-reactive protein; DMARD, disease modifying antirheumatic drug. | ||||||
Goldbach-Mansky et al. Arthritis Res 2000 2:236 doi:10.1186/ar93 |
||||||